Skip to main content
Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

Multiple Myeloma: A Study of C-220 as a Single Treatment and in Combination with Other Treatments

Research Question:
What is the maximum tolerated dose, safety, and efficacy of CC-220 as a single therapy and in combination with other treatments in subjects with Multiple Myeloma?

Basic Study Information

Purpose:
This is a multicenter, multi-country study consisting of two parts: Part 1) Evaluation of dosing amounts of CC-220 alone, CC-220 in combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with DEX and BTZ, and CC-220 in combination with DEX and CFZ; Part 2) Expansion of the highest tolerated doses of CC-220 alone, CC-220 in combination with DEX (DoubleT) for Relapsed Refractory Multiple Myeloma and CC-220 in combination with DEX and BTZ for Newly Diagnosed Multiple Myeloma.

Location: University of Rochester Medical Center
Study Reference #: IMMY19114

Lead Researcher (Principal Investigator)

Lead Researcher:  Brea Lipe

Study Contact Information

Study Coordinator: Stephanie Short
Phone: (585) 276-7885
Email: Stephanie_Short@URMC.Rochester.edu

Additional Study Details

Return to Search